PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.41%
Revenue growth above 1.5x AVGO's 6.32%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
11.96%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-19.51%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-19.51%
Negative operating income growth while AVGO is at 1.00%. Joel Greenblatt would press for urgent turnaround measures.
-16.72%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
-18.75%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-14.34%
Share reduction while AVGO is at 0.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
2.39%
Diluted share count expanding well above AVGO's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
129.66%
OCF growth above 1.5x AVGO's 9.32%. David Dodd would confirm a clear edge in underlying cash generation.
392.13%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
186.63%
10Y revenue/share CAGR under 50% of AVGO's 416.86%. Michael Burry would suspect a lasting competitive disadvantage.
186.63%
5Y revenue/share CAGR 1.25-1.5x AVGO's 134.28%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
186.63%
3Y revenue/share CAGR above 1.5x AVGO's 62.33%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
786.36%
10Y OCF/share CAGR 1.25-1.5x AVGO's 580.47%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
786.36%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
786.36%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
246.81%
Below 50% of AVGO's 869.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
246.81%
5Y net income/share CAGR at 50-75% of AVGO's 414.43%. Martin Whitman might see a shortfall in operational efficiency or brand power.
246.81%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
410.21%
Below 50% of AVGO's 862.23%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
410.21%
5Y equity/share CAGR above 1.5x AVGO's 165.61%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
410.21%
3Y equity/share CAGR above 1.5x AVGO's 201.93%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.49%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-3.49%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
6.43%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
33.31%
BV/share growth above 1.5x AVGO's 5.15%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.08%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
18.01%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
11.29%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.